Medicare’s Part D drug benefit enters 2026 with an annual out-of-pocket threshold of $2,100, up $100 from the year before, and the Centers for Medicare & Medicaid Services says once an enrollee’s spending crosses that line, no further cost sharing applies to covered drugs for the rest of the calendar year. The increase comes from a formula written into the Inflation Reduction Act of 2022 rather than a number Congress revisits annually, which means the cap moves on its own schedule tied to national drug-spending growth. For someone managing a chronic condition on brand-name medication, the distance between $2,000 and $2,100 is real money, and the larger story is what happens on either side of that line.
How Enrollees Reach the $2,100 Line
Before reaching the point where spending stops, a Part D enrollee moves through two phases rebuilt under the 2022 law. The annual deductible for 2026 is $615, during which an enrollee pays the full negotiated price of covered drugs. Once the deductible is met, the initial coverage phase begins, and the enrollee pays 25 percent coinsurance on covered drugs while plan sponsors typically cover 65 to 75 percent of the remaining cost, depending on whether the drug carries a negotiated price. That structure runs continuously until the enrollee’s combined deductible and coinsurance spending reaches the CY 2026 annual out-of-pocket threshold of $2,100, at which point the obligation stops entirely for the rest of the year.
That figure is not an arbitrary round number picked for 2026. CMS describes it as the original $2,000 cap set for 2025, adjusted upward by the annual percentage increase in average Part D drug expenditures nationwide for the prior year. The indexing method means the threshold is likely to move again in future years, though no CMS document has yet published a 2027 figure, and no dollar amount beyond 2026 has been finalized anywhere in the agency’s public guidance. The mechanism matters because it ties a benefit cap that once required congressional action to a formula embedded directly in the Inflation Reduction Act’s Part D redesign.
The practical effect falls hardest on enrollees whose annual drug costs land close to the threshold in either direction. An enrollee whose covered costs reached $2,000 in 2025 crossed into catastrophic coverage and paid nothing further that year; an enrollee with identical costs in 2026 pays cost sharing on an additional $100 of spending before the cap engages, because the deductible and initial coverage phases now run longer before the threshold is reached. That gap is small in isolation, but an inflation-indexed cap replacing a fixed statutory number means the distance between paying and not paying will keep shifting year to year rather than holding still the way earlier Part D benefit design once did.
Inside the kit: 51 state Medicare cost-help packs, the new Part D out-of-pocket cap, the prior-authorization appeal steps and a medication and cost tracker. Open The Medicare Cost & Coverage Protection Kit.
What Zero Cost Sharing Actually Covers After the Cap
Once an enrollee’s spending crosses $2,100, the benefit moves into what CMS calls the catastrophic phase, and enrollees pay no cost sharing for covered Part D drugs for the remainder of the calendar year. The burden does not disappear, it shifts: plan sponsors typically absorb 60 percent of remaining drug costs, manufacturers provide a discount equal to roughly 20 percent on applicable drugs, and CMS pays a reinsurance subsidy covering 20 to 40 percent of the rest depending on the drug category. For a beneficiary on expensive specialty medication, reaching the cap early in the year can mean thousands of dollars in cost sharing simply stop appearing on pharmacy receipts for the months that follow.
The $2,100 ceiling is not the only protection layered into the 2026 benefit year. Enrollees who use insulin pay no more than the lesser of $35, 25 percent of the Medicare-negotiated price, or 25 percent of a plan’s negotiated price for a month’s supply, a cap that carries over from 2025 under the same law. Adult vaccines recommended by the Advisory Committee on Immunization Practices also carry no cost sharing under Part D, and every Part D sponsor is required to offer the Medicare Prescription Payment Plan, which lets an enrollee convert an unpredictable pharmacy bill into a capped monthly installment rather than paying the full amount at checkout.
Not every dollar an enrollee spends counts toward the $2,100 figure. Monthly Part D premiums are excluded entirely, and CMS’s guidance measures the threshold against out-of-pocket spending on covered drugs during the deductible and initial coverage phases, not total health spending for the year. The manufacturer discount applied to applicable drugs during initial coverage does count toward that running total, which is one reason enrollees on brand-name specialty drugs typically reach the cap faster than someone paying mostly for generics, even when their monthly premiums look similar on paper.
Why the Number Moved From $2,000 to $2,100
The increase did not happen in isolation. CY 2026 is also the first year negotiated prices take effect for selected drugs under the Medicare Drug Price Negotiation Program, and CMS created a new selected drug subsidy so that Part D sponsors receive a government payment equal to 10 percent of a selected drug’s negotiated price during the initial coverage phase. That subsidy is designed to offset the financial risk sponsors take on now that certain high-cost drugs carry government-set prices rather than market prices, and it directly touches how the out-of-pocket threshold interacts with what sponsors, manufacturers and CMS each pay at different points in the benefit.
CMS finalized that guidance alongside a companion policy the same day: the 2026 Medicare Advantage and Part D Rate Announcement, projecting a 5.06 percent average increase, or more than $25 billion, in Medicare Advantage payments to plans for 2026. The two releases were issued together because the Part D risk-adjustment models used to set plan payments had to be rebuilt around the new $2,100 threshold, the $615 deductible, and the negotiated-price provisions taking effect for the first time this year. Plan sponsors bidding for 2026 contracts were required to price their offerings against a benefit structure that did not exist in its current form until the Inflation Reduction Act’s provisions finished phasing in.
CMS’s Final CY 2026 Part D Redesign Program Instructions notes explicitly that the policies set for 2026 are “subject to change in subsequent years,” meaning the $2,100 figure holds only for this calendar year and will be recalculated under the same statutory formula before the next one begins. Enrollees who want to see where their own spending stands relative to the cap can find the deductible, coinsurance and out-of-pocket figures broken down phase by phase in that same CMS guidance, which remains the controlling federal document for how the 2026 Part D benefit is priced and administered.
Tracking Drug Spending Against the Cap
Knowing the $2,100 threshold exists does not tell a beneficiary which of their own prescriptions are pushing spending toward it, what to do when a plan denies a drug before the deductible is even met, or how to compare this year’s costs against last year’s once the numbers reset every January. That gap between the published rule and a household’s own pharmacy bills is where most Part D confusion actually starts.
The Medicare Cost & Coverage Protection Kit is a 10-page kit with the new Part D out-of-pocket cap and a medication and cost tracker.
See The Medicare Cost & Coverage Protection Kit.
This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.
